



Bioscene

Bioscene

Volume- 21 Number- 04

ISSN: 1539-2422 (P) 2055-1583 (O)

www.explorebioscene.com

Tirzepatide: A game changer for Type 2 Diabetes and Obesity Management

Mr. Jomy Jose T; Ms. Habeeb Unnisa; Mr. Kirubakaran T;
Mr. Mohammad Imran

Corresponding Author: **Jomy Jose T**

Abstract

Problem: Managing both glycemic control and obesity in patients with type 2 diabetes presents a significant challenge in clinical practice. Traditional therapies for type 2 diabetes tend to focus on controlling blood sugar levels (hyperglycemia) or managing weight, but rarely address both aspects efficiently. While some medications excel at lowering glucose levels, they may not significantly impact weight loss or may even contribute to weight gain, which can complicate overall disease management. This has led to a search for newer therapeutic approaches, such as tirzepatide, which aim to tackle both hyperglycemia and weight management more effectively. **Approach:** This review evaluates the therapeutic potential of tirzepatide, a dual agonist for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, focusing on its impact on glycemic control, cardiovascular outcomes, and weight management. **Findings:** Tirzepatide offers superior glycemic control compared to traditional therapies, significantly reduces body weight, and demonstrates a favorable cardiovascular risk profile. These benefits arise from its ability to enhance insulin secretion, suppress glucagon levels, curb appetite. **Conclusion:** Tirzepatide stands out as an innovative treatment for type 2 diabetes and obesity, addressing both conditions effectively while offering cardiovascular protection.

Keywords: Tirzepatide, Type 2 diabetes, Obesity, GIP, GLP-1, Glycemic control, Weight loss, Cardiovascular outcomes

Introduction

Type 2 diabetes and obesity is prevalent in a global scale and is still rising, presenting challenges for healthcare professionals. Traditional treatment are often unable in managing glycemic control and obesity, which are the major risk factors for cardiovascular diseases. Tirzepatide is a novel dual agonist for GIP and GLP-1 receptors, has emerged as a promising therapeutic option and it address these challenges. This review discusses the efficacy and safety of tirzepatide in managing type 2 diabetes, obesity treatment and associated cardiovascular outcomes.

Mechanism of Action

Tirzepatide acts on both GIP and GLP-1 receptors, these are the two key hormones involved in glucose regulation and appetite control. The activation of GLP-1 receptors enhances insulin secretion in a glucose-dependent manner, it also suppresses glucagon release, and slows gastric emptying, which collectively improve glycemic control (1, 2). Meanwhile, the stimulation of GIP receptors further improves insulin secretion and the evidence suggesting that GIP may also play a part in fat metabolism and energy homeostasis (3). By targeting both receptors, tirzepatide offers a more comprehensive approach to managing the complex metabolic derangements seen in type 2 diabetes and obesity (4).

Efficacy in Glycemic Control

Clinical trials have demonstrated that tirzepatide provides superior glycemic control compared to existing treatments. In the SURPASS trials, tirzepatide significantly reduced hemoglobin A1c (HbA1c) levels compared to both placebo and the GLP-1 receptor agonist semaglutide (5). The SURPASS-5 trial, for instance, compared tirzepatide with placebo in patients receiving insulin glargine and found that tirzepatide significantly reduced hemoglobin A1c (HbA1c) levels (30). This reduction in HbA1c is attributed to tirzepatide's dual action on both insulin secretion and glucagon suppression, which leads to better postprandial glucose control (6). Another study highlighted that tirzepatide outperformed other GLP-1 receptor agonists, such as semaglutide, in reducing blood glucose levels and improving insulin sensitivity (47). Furthermore, tirzepatide has been shown to achieve these glycemic improvements with a lower risk of hypoglycemia, making it a safer option for patients with type 2 diabetes (7).

Impact on Weight Loss

One of the most compelling benefits of tirzepatide is its effect on weight reduction. In addition to its glycemic benefits, tirzepatide has been shown to promote significant weight loss in patients with type 2 diabetes and obesity. This is primarily due to its appetite-suppressing effects, mediated through GLP-1 receptor activation (8). The SURMOUNT-1 and SURMOUNT-2 trials revealed that patients treated with tirzepatide experienced significant reductions in body weight, with many achieving a weight loss of more than 15% (60). In the SURPASS-1 and SURPASS-2 trials, tirzepatide resulted in greater weight loss compared to semaglutide and other conventional therapies (9). The degree of weight reduction observed with tirzepatide is clinically meaningful, with many patients achieving more than 10% weight loss from baseline (10, 11). These outcomes were further supported by a meta-analysis, which confirmed the superiority of tirzepatide in inducing weight loss compared to other antidiabetic drugs (51).

Cardiovascular Outcomes

Beyond glycemic control and weight loss, tirzepatide offers additional cardiometabolic benefits. Studies have shown that tirzepatide reduces cardiovascular risk factors such as blood pressure, cholesterol levels, and triglycerides (34, 45). The drug's ability to lower cardiovascular events is particularly important for patients with type 2 diabetes, who are at a heightened risk of heart disease. The dual action on GIP and GLP-1 receptors not only improves metabolic health but also provides protective effects on the heart and vasculature (46). A pre-specified meta-analysis of cardiovascular events in tirzepatide-treated patients revealed a reduced risk of major adverse cardiovascular events (MACE) compared to placebo (12). These findings are further supported by studies showing tirzepatide's ability to improve cardiometabolic risk factors, such as reducing blood pressure, improving lipid profiles, and decreasing inflammation markers (13, 14).

Safety Profile

Tirzepatide has been generally well-tolerated in clinical trials. The most common adverse events reported are gastrointestinal in nature, including nausea, vomiting, and diarrhoea, which are consistent with the side effects observed with other GLP-1 receptor agonists (15, 36). However, these side effects are often transient and tend to diminish over time. Importantly, tirzepatide has not been associated with an increased risk of severe hypoglycemia, making it a safer option for long-term use in patients with type 2 diabetes (16). Additionally, tirzepatide's dual mechanism does not appear to exacerbate cardiovascular risk factors, further supporting its safety profile (17). However, rare cases of tirzepatide-induced ketoacidosis have been reported, particularly in non-diabetic patients, underscoring the need for cautious use in specific populations (61). Long-term studies are ongoing to fully assess the safety of tirzepatide, but current data indicate a favorable risk-benefit profile.

Comparison with Semaglutide

Tirzepatide has often been compared with semaglutide, another GLP-1 receptor agonist, due to their similar mechanisms of action. However, tirzepatide offers several advantages over semaglutide, particularly in terms of glycemic control and weight loss (47, 56). In head-to-head trials, tirzepatide consistently outperformed semaglutide in reducing HbA1c levels and promoting weight loss (18). Furthermore, tirzepatide's dual action on both GIP and GLP-1 receptors may confer additional metabolic benefits, such as improved lipid metabolism and enhanced insulin sensitivity (19,20). These advantages make tirzepatide a more comprehensive option for patients who require both glycemic control and weight management.

Clinical Implications

The introduction of tirzepatide into clinical practice has the potential to revolutionize the management of type 2 diabetes and obesity. Its dual action on GIP and GLP-1 receptors addresses both glycemic control and weight reduction, two critical factors in the management of these conditions (21). Moreover, tirzepatide's favorable cardiovascular profile makes it an attractive option for patients at high risk of cardiovascular disease (22). As obesity and diabetes continue to increase in prevalence worldwide, tirzepatide offers a novel and effective therapeutic option for managing these conditions holistically (23).

Future Directions

The future of tirzepatide looks promising, with ongoing research exploring its potential in various therapeutic areas. Studies are investigating its effects on non-alcoholic fatty liver disease (NAFLD), its use in combination with other antidiabetic agents, and its long-term impact on cardiovascular outcomes (33, 37). The dual GIP/GLP-1 receptor agonist tirzepatide is among the furthest developed multi-agonists for diabetes care and has so far displayed promising nephroprotective effects (64). Additionally, there is growing interest in the potential of tirzepatide to address the global obesity epidemic, positioning it as a cornerstone in the treatment of metabolic disorders.

Conclusion

Tirzepatide marks a major breakthrough in the management of type 2 diabetes and obesity. Its dual mechanism of action provides superior glycemic control, substantial weight loss, and a reduced risk of cardiovascular events. As clinical experience with tirzepatide grows, it is likely to become a cornerstone in the management of metabolic diseases. Future studies will continue to elucidate its long-term benefits and potential applications in broader patient populations.

Affiliations

¹Doctor of Pharmacy (Pharm.D) , East West College of Pharmacy Address: Thannickal House , Chalappally P.O , Ezhumattoor, Pathanamthitta, Kerala, India

²Doctor of Pharmacy (Pharm.D) , East West College of Pharmacy Address: upper daira, MG Road Cross, Channapatna, Ramnagara district, Karnataka, India

³Doctor of Pharmacy (Pharm.D), East West College of Pharmacy
DC periyasami colony, Nellinagar, Dharmapuri, India

⁴Doctor of Pharmacy (Pharm.D) East West College of Pharmacy Address: Rupandehi Provision, Maya devi gaupalika, Lumbini , Nepal

References:

1. Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, Capozzi ME, van der Velden WJ, Stutsman C, Cardona GR et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. *JCI Insight* 2020, 5(17).
2. Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, Zoungas S. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. *Nat Med.* 2022;28(3):591–8.
3. Cho YK, La Lee Y, Jung CH. The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and glucose-dependent Insulinotropic Polypeptide Dual Agonist. *J Lipid Atheroscler.* 2023;12(3):213–22.
4. Hankosky ER, Wang H, Neff LM, Kan H, Wang F, Ahmad NN, Griffin R, Stefanski A, Garvey WT. Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis. *Diabetes ObesMetab.* 2024;26(1):319–28.
5. Koffert J, Honka H, Teuho J, Kauhanen S, Hurme S, Parkkola R, Oikonen V, Mari A, Lindqvist A, Wierup N, et al. Effects of meal and incretins in the regulation of splanchnic blood flow. *Endocr Connect.* 2017;6(3):179–87.
6. Taktaz F, Scisciola L, Fontanella RA, Pesapane A, Ghosh P, Franzese M, Tortorella G, Puocci A, Sommella E, Signoriello G, et al. Evidence that tirzepatide protects against diabetes-related cardiac damages. *Cardiovasc Diabetol.* 2024;23(1):112.
7. Sinha R, Papamargaritis D, Sargeant JA, Davies MJ. Efficacy and safety of tirzepatide in type 2 diabetes and obesity management. *Journal of obesity & metabolic syndrome.* 2023 Mar 3;32(1):25.
8. Lv X, Wang H, Chen C, Zhao Y, Li K, Wang Y, Wang L, Fu S, Liu J. The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. *Diabetes, Metabolic Syndrome and Obesity.* 2024 Dec 31:701-14.
9. Corrao S, Pollicino C, Maggio D, Torres A, Argano C. Tirzepatide against obesity and insulin-resistance: pathophysiological aspect and clinical evidence. *Frontiers in Endocrinology.*;15:1402583.
10. Haw JS, Farrokhi F, Smiley D, Peng L, Reyes D, Newton C, Pasquel FJ, Vellanki P, Umpierrez GE. Comparison of basal insulin regimens on glycemic variability in noncritically ill patients with type 2 diabetes. *Endocrine Practice.* 2015 Dec 1;21(12):1333-43.
11. Bays HE, Bindlish S, Clayton TL. Obesity, diabetes mellitus, and cardiometabolic risk: an obesity medicine association (OMA) clinical practice statement (CPS) 2023. *Obesity Pillars.* 2023 Mar 1;5:100056.
12. Bays HE. Why does type 2 diabetes mellitus impair weight reduction in patients with obesity? A review. *Obesity Pillars.* 2023 Sep 1;7:100076.

13. Gallwitz B. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. *Frontiers in Endocrinology*. 2022 Oct 13;13:1004044.
14. Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. *Diabetes, Obesity and Metabolism*. 2018 Feb;20:5-21.
15. Lin F, Yu B, Ling B, Lv G, Shang H, Zhao X, Jie X, Chen J, Li Y. Weight loss efficiency and safety of tirzepatide: A Systematic review. *PLoS One*. 2023 May 4;18(5):e0285197.
16. Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. *Cardiovascular diabetology*. 2022 Sep 1;21(1):169.
17. Várkonyi TT, Pósa A, Pávó N, Pavo I. Perspectives on weight control in diabetes–Tirzepatide. *Diabetes Research and Clinical Practice*. 2023 Aug 1;202:110770.
18. Levine JA, Cheng AY, Lingvay I, Valderas EG, Allen SE, Ranta K, Thieu VT, Hamann A. Achievement of HbA1c \leq 6.5% (47.5 mmol/mol), with \geq 10% weight loss, without hypoglycemia in patients treated with tirzepatide vs. comparators in SURPASS program. *Diabetologie und Stoffwechsel*. 2023 Apr;18(S 01):P-114.
19. Patel H, Khunti K, Rodbard HW, Bajaj HS, Bray R, Kindracki Z, Rodriguez A. Tirzepatide-induced weight loss in type 2 diabetes is independent of nausea, vomiting, or diarrhoea. In *Diabetologia* 2022 Sep 1 (Vol. 65, No. SUPPL 1, pp. S290-S291).
20. Brown K, Lando LF, Bergman B, Thomas MK, Liu B, Lee C. 337-OR: Tirzepatide Improved Markers of Islet-Cell Function (Fasting Glucagon and HOMA2-B) and Insulin Sensitivity (Fasting Insulin and HOMA2-IR) Compared with Semaglutide in People with Type 2 Diabetes. *Diabetes*. 2022 Jun 1;71(Supplement_1).
21. Niu S, Jiao T, Guo Y, Bian J, Shi L, Fonseca V, Shao H. 256-OR: five-year simulation of diabetes-related complications in individuals treated with once-weekly tirzepatide and semaglutide vs. once-daily insulin glargine. *Diabetes*. 2022 Jun 1;71(Supplement_1).
22. Heise T, Mari A, DeVries JH, Urva S, Li J, Pratt EJ, Coskun T, Thomas MK, Mather KJ, Haupt A, Milicevic Z. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. *The Lancet Diabetes & Endocrinology*. 2022 Jun 1;10(6):418-29.
23. Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. *Cardiovascular diabetology*. 2022 Sep 1;21(1):169.
24. Frias JP, Davies M, Rosenstock J, Manghi FP, Landó LF, Bergman BK, Liu B, Cui X, Brown K, Nauck M, Seufert J. Efficacy and safety of tirzepatide versus semaglutide once weekly as add-on therapy to metformin in people with type

- 2 diabetes (SURPASS-2). *Diabetologie und Stoffwechsel*. 2022 May;17(S 01):P-010.
25. Gandhi GY. In type 2 diabetes, tirzepatide reduced HbA1c vs. semaglutide. *Annals of Internal Medicine*. 2021 Nov;174(11):JC127.
26. Jung HN, Jung CH. The upcoming weekly tides (semaglutide vs. tirzepatide) against obesity: STEP or SURPASS?. *Journal of obesity & metabolic syndrome*. 2022 Mar 3;31(1):28.
27. Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Lando LF, Bergman B, Liu B, Cui X, Brown K. 84-LB: Efficacy and safety of tirzepatide vs. Semaglutide once-weekly as add-on therapy to metformin in people with type 2 diabetes (SURPASS-2). *Diabetes*. 2021 Jun 1;70(Supplement_1).
28. Azuri J, Hammerman A, Aboalhasan E, Sluckis B, Arbel R. Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis. *Diabetes, Obesity and Metabolism*. 2023 Apr;25(4):961-4.
29. Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. *Jama* (2022) 327(6):534–45.
30. Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. *JCI Insight* (2020) 5(17).
31. Gasbjerg LS, Bergmann NC, Stensen S, Christensen MB, Rosenkilde MM, Holst JJ, et al. Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. *Peptides* (2020) 125:170183.
32. Cignarella A, Busetto L, Vettor R. Pharmacotherapy of obesity: An update. *Pharmacol Res* (2021) 169:105649.
33. Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. *Cardiovascular Diabetol* (2021) 20(1):1– 5.
34. Farzam K, Patel P. Tirzepatide. In: *StatPearls* [Internet]. StatPearls Publishing (2022).
35. Ali R, Virendra SA, Chawla PA. Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist. *Health Sci Rev* (2022) 4:100032.
36. Iwamoto Y, Kimura T, Dan K, Iwamoto H, Sanada J, Fushimi Y, Katakura Y, Shimoda M, Yamasaki Y, Nogami Y, Shirakiya Y. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β -cells and hepatic steatosis in obese type 2 diabetic db/db mice. *Diabetes, Obesity and Metabolism*. 2024 Sep 30.
37. Gible TM, Cao D, Murphy M, Jouravskaya I, Liao B. 5184 Tirzepatide Improved Mental and Psychosocial Health-Related Quality of Life in Adults with Obesity

- or Overweight: Results from the SURMOUNT-4 phase 3 Trial. *Journal of the Endocrine Society*. 2024 Oct;8(Supplement_1):bvae163-044.
38. Cariou B, Linge J, Neeland IJ, Dahlqvist Leinhard O, Petersson M, Fernández Landó L, Bray R, Rodríguez Á. Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes. *Diabetes, Obesity and Metabolism*. 2024 Jun;26(6):2446-55.
 39. Williamson DA, Bray GA, Ryan DH. Is 5% weight loss a satisfactory criterion to define clinically significant weight loss?. *Obesity*. 2015 Dec 1;23(12):2319.
 40. Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. *The lancet Diabetes & endocrinology*. 2018 Mar 1;6(3):237-48.
 41. Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. *The Lancet*. 2022 Jan 22;399(10322):394-405.
 42. Lingvay I, Cohen RV, le Roux CW, Sumithran P. Obesity in adults. *The Lancet*. 2024 Sep 7;404(10456):972-87.
 43. Chandrasekaran P, Weiskirchen R. The role of obesity in type 2 diabetes mellitus—An overview. *International Journal of Molecular Sciences*. 2024 Feb 4;25(3):1882.
 44. Rabbani SA, El-Tanani M, Matalka II, Rangraze IR, Aljabali AA, Khan MA, Tambuwala MM. Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management. *Expert Review of Endocrinology & Metabolism*. 2024 Aug 30:1-9.
 45. Taktaz F, Scisciola L, Fontanella RA, Pesapane A, Ghosh P, Franzese M, Tortorella G, Puocci A, Sommella E, Signoriello G, Olivieri F. Evidence that tirzepatide protects against diabetes-related cardiac damages. *Cardiovascular Diabetology*. 2024 Mar 30;23(1):112.
 46. Mather KJ, Mari A, Heise T, DeVries JH, Hua M, Urva S, Coskun T, Haupt A, Heine RJ, Pratt E, Thomas MK. Effects of Tirzepatide vs Semaglutide on β -cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test. *The Journal of Clinical Endocrinology & Metabolism*. 2024 May 26:dgae319.
 47. Anson M, Henney AE, Broadwell N, Zhao SS, Ibarburu GH, Lip GY, Wilding JP, Cuthbertson DJ, Alam U. Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study. *EClinicalMedicine*. 2024 Sep 1;75.
 48. Vázquez LA, Tofé-Povedano S, Bellido-Guerrero D, Botella-Serrano M, Soto-González A, Mezquita-Raya P, Delgado E, Fajardo-Montañana C, Morales-Portillo C, Causanilles A, Rubio-de Santos M. Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects. *Diabetes Therapy*. 2024 May 9:1-2.
 49. Cariou B, Linge J, Neeland IJ, Dahlqvist Leinhard O, Petersson M, Fernández Landó L, Bray R, Rodríguez Á. Effect of tirzepatide on body fat distribution

- pattern in people with type 2 diabetes. *Diabetes, Obesity and Metabolism*. 2024 Jun;26(6):2446-55.
50. Ala M, Mohammad Jafari R, Dehpour AR, Poursalehian M. Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials. *International Journal of Obesity*. 2024 Aug 29:1-2.
51. Strollo F, Guarino G, Satta E, Gentile S. Tirzepatide: A Double Agonist for Various People Living with Type 2 Diabetes. *Diabetes Therapy*. 2024 Sep;15(9):1855-60.
52. Cui Y, Yao J, Qiu X, Guo C, Kong D, Dong J, Liao L. Comparative Efficacy and Safety of Tirzepatide in Asians and Non-Asians with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. *Diabetes Therapy*. 2024 Apr;15(4):781-99.
53. Bi Y, Lu S, Tang J, Du L, Ji L. Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups. *Diabetes Therapy*. 2024 May;15(5):1125-37.
54. Barakat S, Ramdeen S, Khaimova R. Safety and Efficacy of Switching Patients With Type 2 Diabetes From Glucagon-Like Peptide-1 Receptor Agonists to Tirzepatide: A Case Series. *Hospital Pharmacy*. 2024 Dec
55. Mody R, Valentine WJ, Hoog M, Sharland H, Belger M. Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-term cost-effectiveness analysis in patients with type 2 diabetes in the United States. *Journal of Managed Care & Specialty Pharmacy*. 2024 Feb 3;30(2):153-62.
56. Suzuki T, Sato T, Tanaka M, Endo K, Nakata K, Ogawa T, Hosaka I, Akiyama Y, Umetsu A, Furuhashi M. Tirzepatide ameliorates eating behaviors regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus. *Journal of Diabetes and its Complications*. 2024 May 29:108779.
57. Varadhan L, Humphreys T, Walker AB, Varughese GI. The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy. *Diabetes Res Clin Pract*. 2014;103(3):e37-e39.
58. Jalleh RJ, Plummer MP, Marathe CS, Umapathysivam MM, Quast DR, Rayner CK, Jones KL, Wu T, Horowitz M, Nauck MA. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. *The Journal of Clinical Endocrinology & Metabolism*. 2024 Oct 17:dgae719.
59. Galindo Rj, Timothy Garvey W, Neff Lm, Stefanski A, Cao D, Lee C. 231-OR: Differences in Weight Reduction Efficacy of Tirzepatide in Adults Without vs. With Type 2 Diabetes with Overweight or Obesity in SURMOUNT 1 and 2. *Diabetes*. 2024 Jun 14;73(Supplement_1).
60. Iqbal PM, Maadarani OS, Bitar ZI. Tirzepatide-induced ketoacidosis in non-diabetic patients. *European Journal of Case Reports in Internal Medicine*. 2024;11(4).

61. Mody R, Desai K, Teng Cc, Reznor G, Stockbower G, Grabner M, Benneyworth Bd. 744-P: Dosing Patterns of Tirzepatide (TZP) in Patients with Type 2 Diabetes (T2D) from a Commercially Insured US Population. *Diabetes*. 2024 Jun 14;73(Supplement_1).
62. Hunter T, Gibble TH, Cao D, Zhang XM, Xavier NA, Poon JL. # 1704957 Tirzepatide Improves Health-Related Quality of Life in Participants With Obesity or Overweight and Type 2 Diabetes: Results From Phase 3 SURMOUNT-2 Trial. *Endocrine Practice*. 2024 May 1;30(5):S70.
63. Kosaraju SA, Zhang RM. Tirzepatide Prescribing Practices and Efficacy in Patients with Diabetes and Chronic Kidney Disease at a Large Tertiary Care Center in the United States. *Diabetes, Metabolic Syndrome and Obesity*. 2024 Dec 31:3621-8.
64. Caruso I, Giorgino F. Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future. *Endocrine*. 2024 Mar 12:1-4.